Role of BATAN in Establishing Nuclear

Oncology in Indonesia

Hudi Hastowo

Badan Tenaga Nuklir Nasional-BATAN

5 November 2009
BATAN has the following functions :

l To assess and prepare the national policy in the field of

research, development, and the beneficial uses of nuclear
energy:
l Food, energy, health, etc

l To support and foster activities of government institutions in

the field of research, development and beneficial uses of
nuclear energy,

l Liaison officer to the international institution dealing with

nuclear activities: IAEA, FNCA, others
The Burden of Cancer
l Cancer kills 7 million people each year
l 25 million live with cancer; over 10 million new cases this
year, more than half in developing countries and increasing
l By 2020, cancer could kill over 10 million, while new cases
could rise to 16 million per year unless we act
l Radiation and nuclear oncology is an essential and integral
component of cancer care
l In spite of assistance programs, developing countries not
able to deal with this epidemic today
l More than 2 million lives can be saved by 2020 if
appropriate measures are put in place to prevent, detect
early, diagnose, and cure
Massoud Samiei, IAEA
PACT: IAEA’s Response …
l Program of Action for Cancer Therapy (PACT) is the
IAEA’s response to the cancer challenge in developing
countries

• The long-term objective of PACT is:

Sustainable National Capacity for Cancer Care

The Vision for PACT

l Build sustainable national cancer care infrastructure and

capacity towards eventual self-sufficiency through South-
South and North-South partnerships
l Systematically plan and build capacity to diagnose and
treat all patients with radiosensitive cancers
l Focus on eliminating all cancer morbidity and mortality
from unmet treatment needs among patients for whom
radiotherapy is most effective
l Deploy consistent and predictable resources and
processes including investments from private donors to
meet these objectives over a 5 to 10 year strategy

Massoud Samiei, IAEA

PACT is being operationalised using
specific mechanisms such as imPACT
(integrated missions of PACT)
The imPACT Review will:

l Assist governments to review, analyse and

formulate National Cancer Strategies and Action
Plans for capacity building from prevention through
palliation
l Enable institutions to build and develop human
resources and plans for capacity in radiation and
nuclear oncology
The results of imPACT will enable governments
to:
l Work with partners
l Focus on centres of competence/reference to deliver
quality cancer care
l Raise public awareness of cancer prevention,
diagnosis, and therapy
l Apply best practices, expand and continue
professional development
Massoud Samiei, IAEA
IAEA Ministry of Research Ministry of Health
& Technology

DG of Disease Control
National Nuclear DG of Medical Care,
& Environmental Health,
Energy Agency Ministry of Health
Ministry of Health
(BATAN)

Dharmais Cancer Hospital,

National Cancer Center

PACT National Cancer Control Program

• Cancer Diagnosis • Prevention
• Cancer Treatment • Early detection
• Diagnosis
• Treatment
PACT Fundamentals
• National Cancer Control Programs:
Ø Prevention
Ø Early Detection
Ø Diagnosis and Treatment
Ø Palliative Care
• Radiation Medicine and the role of the BATAN
and the IAEA

* Radiation Medicine includes both radiotherapy (or radiation

oncology) and diagnostic imaging involving the safe use of
ionizing radiation and nuclear medicine procedures.
BATAN’s Role for PACT/Nuclear Oncology:

• Carry out R&D on radiopharmaceuticals, RIA/IRMA Kits,

and brachytherapy sealed sources for PACT
• Encourage national companies, such as PT Kimia Farma,
PT Batan Technology to produce and distribute products for
PACT developed by BATAN
• Provide services to nuclear instruments associated with
PACT
Radiopharmaceuticals developed by BATAN
for Nuclear Oncology:
l PET and SPECT radiopharmaceuticals, such as 18FDG,
18FLT, 123I-MIBG, 99mTc-HYNIC Octreotide, 99mTc-HYNIC-

Folate, etc.
l Therapeutic radiopharmaceuticals:
- 153Sm-EDTMP
- 186Re-HEDP
- 131I-MIBG
- 131I-Lipiodol
- 177Lu-DOTA-Nimotuzumab
177 Radioimmunotherapy
- Lu-DOTA-Trastuzumab

l PZC-Based 188W/188Re Therapeutic Generator

RIA Kits developed by BATAN for Nuclear
Oncology:

• IRMA Kit CA 125 for in vitro diagnosis of ovarium cancer

• IRMA Kit CA 15.3 for in vitro diagnosis of breast cancer
 Sealed Sources developed by BATAN for
Nuclear Oncology:
l
125I
Seed sealed sources for seed brachytherapy of
prostate cancer

l
192Irneedle sealed sources for HDR/LDR brachytherapy
for cervics cancer, etc.
BATAN’s Facility for Producing Radionuclide of 125I
BATAN’s Laser Welder for preparing 125I seed and 192Ir needle
sealed-sources
 125I seed sealed-sources

Brachytherapy of Prostate
Cancer using 125I seeds
 Program Action BATAN’s Contribution
• Develop RIA/IRMA Kits, PET and
• Early Detection SPECT radiopharmaceuticals as
required by Hospitals involved in
PACT
• Diagnosis • Develop PET and SPECT
radiopharmaceuticals as required by
Hospitals involved in PACT
• Develop sealed sources (needle,
seed)for HDR and LDR
• Treatment or Therapy Brachytherapy, CND Brachytherapy,
Targeted Therapeutic
Radiopharmaceuticals
• Develop simple and targeted
• Palliative Care
therapeutic radiopharmaceuticals
Summary

• BATAN will actively involve to support PACT through the

R&D programs in the health field.
• BATAN will encourage a close relationship and
communication between BATAN’s Centers with
hospitals/medical doctors to develop
radiopharmaceuticals/RIA and IRMA Kits, sealed
sources for brachytherapy suitable for local condition.
THANK YOU